Drug Disease Relationships
Drug Disease Relationships - Related Videos
01:28
Structure-Activity Relationships and Drug Design
0 Views •
2024
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs. SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
02:12
Relationship Formation
0 Views •
2020
What do you think is the single most influential factor in determining with whom you become friends and whom you form romantic relationships? You might be surprised to learn that the answer is simple: the people with whom you have the most contact. This most important factor is proximity. You are more likely to be friends with people you have regular contact with. For example, there are decades of research that shows that you are more likely to become friends with people who live in your dorm,...
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
0 Views •
Cited by 4 •
2016
Here we describe a protocol using the web-based drug repurposing hypothesis generation tool: "RE:fine Drugs." This protocol can be modified to a user's preferences at the level of the query type (gene, drug or disease) and/or the range of available advanced options.
05:21
Evolutionary Relationships - Concepts
0 Views •
2019
Humans have been attempting to properly classify living things since Aristotle made the first attempt during the 4th century BC. Aristotle’s system was improved upon during the Renaissance and then, subsequently, by Carolus Linnaeus in the mid 1700’s. These more formal classification and organization systems grouped species by their physical similarity to one another. For example, all vertebrates have a backbone, but invertebrates do not. Traits like the backbone are called synapomorphies,...
07:32
Evolutionary Relationships - Student Protocol
0 Views •
2019
Forming an Evolutionary Hypothesis ExpandNOTE: A cladogram is an important tool for forming an evolutionary hypothesis. A cladogram is a tree-shaped chart used to depict the hypothetical genealogical relationships between species. The tips or leaves of the chart represent specific species and the branches of the tree are different lengths. The different lengths represent the degree of change between each of the species. The common ancestor of all of the species that a specific line branches...
FAQs
Pharmacodynamic effects depend on how a medication activates or blocks receptors involved in a pathological process. The clinical result therefore reflects the relationship between the drug’s target and the disease mechanism, not simply the presence of illness. This perspective helps clinicians connect a treatment’s intended action with its therapeutic value and potential adverse effects.
Disease can change pharmacokinetic processes, including absorption, distribution, metabolism, or elimination. When these processes are affected, the amount of drug reaching relevant tissues or remaining in the body may change, which can modify effectiveness and safety. Recognizing these changes supports dose adjustment and helps clinicians avoid treatment plans that produce inadequate or excessive drug effects.
A medication may be inappropriate when its mechanism conflicts with the biology of a disease or when illness increases the likelihood of harmful effects. Drug disease relationships therefore help identify contraindications, meaning circumstances in which a treatment should not be used. This assessment adds a disease-specific safety check beyond considering the medication in isolation.
Clinicians evaluate how a candidate medication’s mechanism, therapeutic value, safety profile, and pharmacokinetic behavior fit the patient’s disease. They can then select a treatment and determine whether dose adjustment is needed because of illness-related changes. This structured assessment links prescribing decisions to both the biological problem being treated and the patient’s expected response.
Dose decisions should account for whether disease has altered absorption, distribution, metabolism, or elimination, as well as whether the medication’s effects could worsen illness-related risks. Clinicians also consider therapeutic outcomes and adverse effects after treatment begins. These factors provide a basis for refining therapy rather than applying the same dose independently of disease status.
When patients receive multiple medications, disease-specific effects can influence the safety and therapeutic value of the overall regimen. Applying this framework supports personalized prescribing by matching treatment choices and doses to individual disease characteristics. It also helps clinicians interpret outcomes, anticipate adverse effects, and develop therapies aimed at biological mechanisms underlying particular diseases.